RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
Simon JA, Kingsberg SA, Shumel B, et al.
The Journal of Sexual Medicine, 2020 · n = 620
Key finding
Bremelanotide improved desire domain scores (mean difference 3.9 vs 2.6 placebo, p<0.001) and reduced sexual distress significantly.
Summary
Second pivotal Phase 3 trial confirming bremelanotide efficacy in premenopausal women with generalized HSDD across 12 weeks of treatment.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
Skin Hyperpigmentation with Melanocortin-4 Receptor Agonists: Predictors and Prevention
The Journal of Sexual Medicine · 2020 · Human Pilot